# Program 1: Therapeutic Development Program (TDP)

> **NIH NIH P30** · UNIVERSITY OF ARIZONA · 2020 · $1,000,000

## Abstract

Project Summary / Abstract: Therapeutic Development Program (TDP) 
The scientific goal of the Therapeutic Development Program (TDP) of the University of Arizona Cancer Center 
(UACC) is to develop strategies that can be used to expand available therapeutic options and / or lead to 
enhanced efficacy of existing therapeutics. The Program leverages internal basic research expertise in the 
study of molecular pathways that mediate cancer growth, including specialized capabilities in target discovery, 
molecular modeling, and chemical synthesis with analogue development, refinement of novel molecule-based 
therapeutics, and extensive analysis of predictive biomarkers. Program activities are organized under three 
major themes: 1) Chemically synthesize and biologically characterize novel anti-cancer agents, 2) Elucidate 
unique biologic targets for new chemotherapy agents, and 3) Translate laboratory findings into clinical trials. In 
the past 6 years, the Program has initiated and participated in 36 interventional trials. Currently, 19 
interventional investigator-initiated trials (IITs) are open and recruiting patients at the UACC. The capabilities of 
the TDP have been expanded greatly by the recent expansion of the UACC-affiliated clinical facilities, the 
strategic recruitment of 13 clinicians and researchers, and its inclusive training and mentoring environment. 
The TDP Members lead and participate in the UACC Disease-Oriented Teams, which have promoted 
collaborations within TDP and with the three other UACC Research Programs. The Members focus on targets 
and precision medicine approaches of potential relevance to clinical cancer applications with an emphasis on 
the cancer burden in the catchment area, including skin, breast, lymphoma, and gastrointestinal cancers. TDP 
Members have published 547 cancer-relevant manuscripts, of which 19% are intra-programmatic and 24% 
inter-programmatic. The significance of the Program is indicated by publication in very high impact journals (4 
NEJM, 3 Nature, 1 Nature Genetics, 4 PNAS, 2 Lancet, 4 Lancet Oncology, and 1 J Invest Dermatol); its entry 
of 3 new first-in-the-field drugs into Phase II studies and commercial development; and its introduction of 
several new diagnostic/prognostic technologies into national validation trials, one of which is now marketed. 
Currently, the Program has 53 Members representing 19 different departments. As of September 1, 2015, the 
TDP Program secured $8.3M in total annual grant dollars with $2.6M of that from the NCI and $4.2M in other 
peer-reviewed funding.

## Key facts

- **NIH application ID:** 10207497
- **Project number:** 3P30CA023074-40S2
- **Recipient organization:** UNIVERSITY OF ARIZONA
- **Principal Investigator:** WILLIAM R. MONTFORT
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $1,000,000
- **Award type:** 3
- **Project period:** 1997-07-01 → 2022-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10207497

## Citation

> US National Institutes of Health, RePORTER application 10207497, Program 1: Therapeutic Development Program (TDP) (3P30CA023074-40S2). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10207497. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*